Boston Scientific BSX Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Net sales of reportable segments by Business | ||||||
| Cardiovascular | $13.64B+18.2% | $13.29B+22.6% | $12.8B+24.9% | $12.22B+26.2% | $11.54B+25.2% | |
| MedSurg | $6.93B+11.3% | $6.84B+13.4% | $6.67B+13.4% | $6.44B+12.4% | $6.22B+11.4% | |
| Net Sales by Product | ||||||
| Cardiac Rhythm Management | $2.33B+2.2% | $2.33B+2.4% | $2.31B+2.1% | $2.3B+1.7% | $2.28B+1.6% | |
| Electrophysiology | $3.5B+50.0% | $3.33B+74.6% | $3.08B+106% | $2.75B+137% | $2.33B+153% | |
| Endoscopy | $2.98B+9.6% | $2.92B+8.5% | $2.85B+7.8% | $2.78B+7.2% | $2.72B+6.7% | |
| Neuromodulation | $1.25B+11.3% | $1.2B+8.6% | $1.17B+8.6% | $1.14B+10.2% | $1.12B+12.3% | |
| Urology | $2.72B+17.3% | $2.71B+23.1% | $2.62B+25.0% | $2.47B+20.7% | $2.32B+15.5% | |
| Watchman | $2.04B+27.7% | $1.96B+29.2% | $1.84B+26.9% | $1.7B+22.6% | $1.6B+20.3% | |
| Net Sales by Geography | ||||||
| Asia-Pacific | $3.18B+16.2% | $3.08B+14.7% | $2.98B+13.8% | $2.86B+12.4% | $2.74B+9.6% | |
| Europe, Middle East and Africa | $3.54B+8.1% | $3.45B+6.9% | $3.35B+6.4% | $3.33B+9.3% | $3.27B+11.0% | |
| Latin America and Canada | $708M+12.2% | $678M+8.5% | $654M+5.8% | $638M+5.5% | $631M+8.2% | |
| U.S. | $13.19B+20.8% | $12.86B+26.0% | $12.37B+29.8% | $11.67B+29.2% | $10.91B+25.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Boston Scientific break its business down?
- Boston Scientific (BSX) reports net sales of reportable segments by business across 2 parts — Cardiovascular and MedSurg. Each is extracted from the segment footnotes and tracked over time.
- Where does Boston Scientific's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Boston Scientific's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
